Growth Hormone Secretagogue Therapy Provides Effective Relief of Most Symptoms Related to Chronic Fatigue Syndrome in a Prospective Patient-Centered Outcome Study

02-01-1999

Advertisement

Recent research suggests that low growth hormone levels characterized by low IGF-1 levels are linked to some patients diagnosed with Chronic Fatigue Syndrome. Researchers in this study treated patients by using plant-derived, bioactive polypeptides which are proven to raise IGF-1 levels. Fourteen CFS patients were treated once daily five times a week, for a period of ninety days. A clinical questionnaire was administered to determine patient-defined outcomes while patient outcomes were assessed using a physician-assigned score of global response. Both physician and patient assessments reported that 57% of patients reported a beneficial response ranging from fair to excellent. Although the improvement of symptoms was broad-based, muscle pain and fatigue were the most responsive symptoms to the treatment. The administration of the plant derived polypeptides were shown to normalize IGF-1 levels in patients reporting improvements.

Every purchase funds research, donations and the community resources provided within our website.